We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Burnley-Moran and Johnson elementary schools in Charlottesville will have new names at the start of the next school year.

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

SRPT insiders have traded $SRPT stock on the open market 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales. Here’s a ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at $75.00. Discover outperforming stocks and ...

Moreover, the ongoing progress in Sarepta’s pipeline, particularly in the limb-girdle muscular dystrophy programs and other early-stage studies, supports a positive long-term growth trajectory.

Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys. The company reported ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year ...